Alzheon Raises $100 Million Series E Financing Round to Advance Development and Commercialization of Oral Tablet ALZ-801/Valiltramiprosate for Treatment of Alzheimer’s Disease
Summary
Alzheon previously raised $50 million through a Series D financing round in 2022.Alzheon has experienced tremendous progress in the past year and the promise of our novel oral Alzheimers treatment, ALZ-801, has attracted prominent institutional and private investors. Our ability to raise $150 million over the last two financing rounds in the current climate speaks volumes about the prospects of our innovative science and technology, said Martin Tolar, MD, PhD, Founder, President, and CEO of Alzheon. ALZ-801 has shown potential for robust clinical efficacy in the highest-risk AD population patients with two copies of the apolipoprotein 4 allele (APOE4/4 homozygotes), and favorable safety with no increased risk of brain vasogenic edema. An ongoing long-term extension of the trial evaluates ALZ-801 for an additional 104 weeks of treatment for a total of 208 weeks.An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early Alzheimers Disease Subjects (NCT04770220): This ongoing trial is designed to evaluate the efficacy, safety, biomarker and imaging effects of 265 mg twice daily oral dose of ALZ-801 in Early AD subjects with two copies of the apolipoprotein 4 allele (APOE4/4 homozygotes), who constitute approximately 15% of Alzheimers patients. An ongoing long-term extension of the trial evaluates ALZ-801 for an additional 52 weeks of treatment for a total of 130 weeks.Alzheon, Inc. is a clinical-stage biopharmaceutical company developing a broad portfolio of product candidates and diagnostic assays for patients suffering from Alzheimers disease and other neurodegenerative disorders.